Download Image
    
Share
  
Post
Acebilustat for COVID-19
1 study with 120 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Acebilustat
No significant improvements are seen in meta analysis to date.
COVID-19 Acebilustat studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Hospitalization 0% RCTs 0% Early 0% Favorsacebilustat Favorscontrol
Mar 30
2023
 Levitt et al., Clinical Infectious Diseases, doi:10.1093/cid/ciad187 Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
80% lower progression (p=0.21), 67% worse recovery (p=0.07), and 6% improved viral clearance. RCT 120 outpatients showing no significant difference in time to sustained symptom resolution or viral clearance with acebilustat treatment. Subgroup analyses showed consistent patterns of longer symptom duration in treated participants.